Diaceutics (GB:DXRX) has released an update.
Diaceutics PLC has reported a 24% revenue growth in the first half of 2024, with recurring revenue constituting 55% of total earnings. The company has expanded its customer base by 26%, now working with 63 individual brands, and boasts a strong cash position of £16.7 million. Their focus on leveraging proprietary AI and strategic enterprise-wide engagements positions them as a primary partner for pharma and biotech companies in the precision medicine space.
For further insights into GB:DXRX stock, check out TipRanks’ Stock Analysis page.
